A 70-year-old woman has undergone the first graft of induced pluripotent stem cells. She is a participant in a clinical trial that is testing stem cells for treating age-related macular degeneration (AMD).
You are here
Coverage of the latest news and updates from the field of stem cells and regenerative medicine.
A new report on the induced pluripotent stem cell (iPSC) product market says it lures major industry competitors with double-digit growth and massive change in 2013.
Scientists at the Ottawa Hospital Research Institute (OHRI) have made what they say is a breakthrough in the treatment of a rare and debilitating neurological disease known as “stiff person syndrome” that leaves people who are afflicted with the disorder standing like tin soldiers and unable to m
As we age, stem cells throughout our bodies gradually lose their capacity to repair damage even from normal wear and tear. Researchers have discovered the reason why this decline occurs in our skeletal muscle.
What if repairing large segments of damaged muscle tissue was as simple as mobilizing the body’s stem cells to the site of the injury? New research suggests that “in body” regeneration of muscle tissue might be possible by harnessing the body’s natural healing powers.
The Food and Drug Administration (FDA) has given approval to begin a clinical trial of a stem cell therapy in patients with spinal cord injury. The phase I/IIa clinical trial is designed to test the safety of AST-OPC1 cells, a product of Asterias Biotherapeutics Inc., Menlo Park, Calif.
Rare stem cells in testes that produce a biomarker protein called PAX7 help give rise to new sperm cells—and may hold a key to restoring fertility.
Researchers at the University of Basel report that initial results of a clinical trial testing cartilage grafts for knees engineered from the patient’s nasal cells is “highly promising.”
Creating induced pluripotent stem cells (iPS cells) allows researchers to establish “disease in a dish” models of conditions ranging from Alzheimer’s disease to diabetes.